The SA Journal Diabetes & Vascular Disease Vol 12 No 1 (July 2015)

13 / 48

SA JOURNAL OF DIABETES & VASCULAR DISEASE REVIEW
VOLUME 12 NUMBER 1 • JULY 2015 11
13. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among
circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk
factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668–1673.
14. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in
cardiovascular risk prediction models for women. Ann Intern Med 2006; 145:
21–29.
15. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of
irregular menses and elevated androgen measurements at high risk for worsening
cardiovascular event-free survival: results from the National Institutes of Health –
National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome
Evaluation. J Clin Endocrinol Metab 2008; 93: 1276–1284.
16. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factors in women. Eur
Heart J 2002; 23:1738–1752.
17. Mitu F, Pop D, Zdrenghea D. Particularităţ i ale bolilor cardiovasculare la femei. Ed.
Clusium. Cluj-Napoca, 2012.
18. Fraser A, May M, Lowe G, et al. Interleukin-6 and incident coronary heart disease:
results from the British Women's Heart and Health Study. Atherosclerosis 2009;
202: 567–572.
19. Danesh J, Kaptoge S, Mann AG, et al . Long-term interleukin-6 levels and
subsequent risk of coronary heart disease: two new prospective studies and a
systematic review. PLoS Med 2008; 5: 78.
20. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-
cardiovascular disease. J Thromb Haemost 2005; 3:1618–1627.
21. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the
associations between seven hemostatic or inflammatory variables and coronary
heart disease. J Thromb Haemost 2007; 5:1795–1800.
22. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the
risk of major cardiovascular diseases and nonvascular mortality: an individual
participant meta-analysis. J Am Med Assoc 2005; 294:1799–1809.
23. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and
genetic markers of coronary heart disease risk in the Women’s Health Initiative
trials of hormone therapy. Arch Intern Med 2008; 168: 2245–2253.
24. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the
associations between seven hemostatic or inflammatory variables and coronary
heart disease. J Thromb Haemost 2007; 5:1795–1800.
25. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which
hemostatic markers add to the predictive value of conventional risk factors for
coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation
2005; 112: 3080–3087.
26. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease:
prospective study and meta-analysis. Circulation 2001; 103: 2323–2327.
27. Rana JS, Cote M, Després JP,et al. Inflammatory biomarkers and the prediction of
coronary events among people at intermediate risk: the EPIC-Norfolk prospective
population study. Heart 2009; 95: 1682–1687.
28. Wassertheil-Smoller S, Kooperberg C, McGinn AP, et al. Lipoprotein-associated
phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal
women. Hypertension 2008; 51: 1115–1122.
29. Hatoum IJ, Cook NR, Nelson JJ, Rexrode KM, Rimm EB. Lipoprotein-associated
phospholipase A2 activity improves risk discrimination of incident coronary heart
disease among women. Am Heart J 2011; 161: 516–522.
30. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B
lipoproteins with arterial proteoglycans: pathological significance and molecular
basis. Atherosclerosis 1998; 139: 205–222.
31. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2)
modification of low density lipoproteins forms small high density particles with
increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999;
274: 25913–25920.
32. Hakala JK, Oorni K, Pentikainen MO, Hurt-Camejo E, Kovanen PT. Lipolysis
of LDL by human secretory phospholipase A(2) induces particle fusion and
enhances the retention of LDL to human aortic proteoglycans. Arterioscler
Thromb Vasc Biol 2001; 21: 1053–1058.
33. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory phospholipase
A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and
nonenzymic lipid peroxidation in low-density lipoproteins. Biochemistry 1998;
37: 9203–9210.
34. Oestvang J, Bonnefont-Rousselot D, Ninio E, Hakala JK, Johansen B, Anthonsen
MW. Modification of LDL with human secretory phospholipase A2 or
sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid
Res 2004; 45: 831–838.
35. Greenland P, Alpert JS, Beller GA,et al. 2010 ACCF/AHA guideline for assessment
of cardiovascular risk in asymptomatic adults: a report of the American College
of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2010; 56:50–103.
36. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives.
The ARIC investigators. Am J Epidemiol 1989; 129: 687–702.
37. Rosenson RS, Hurt-Camejo E. Novel therapeutic concepts: Phospholipase A2
enzymes and the risk of atherosclerosis. Eur Heart J 2012; 33: 2899–2909.
38. Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of
acute thrombosis and sudden coronary death in women. Circulation 1998; 97:
2110–2116.
39. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of
first major cardiovascular events and death. N Engl J Med 2006; 355: 2631–
2639.
40. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional
biomarkers for prediction of incident cardiovascular events in the community. J
Am Med Assoc 2009; 302: 49–57.
41. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K,
et. al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure 2012: The Task Force for
the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration with the Heart
Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.
42. Luchner, A., Behrens, G., Stritzke J, et al. Long-term pattern of brain natriuretic
peptide and N-terminal pro brain natriuretic peptide and its determinants in the
general population: contribution of age, gender, and cardiac and extra-cardiac
factors. Eur J Heart Fail 2013; 15: 859–867.
43. Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification
with B-type natriuretic peptide levels in patients with acute dyspnea: insights
from the B-type natriuretic peptide for acute shortness of breath evaluation
study. J Am Coll Cardiol 2006; 48: 1808–1812.
44. Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk
prediction. J Intern Med 2012; 272: 430–439.
VIt is with sadness that we report the death of Prof Cephas
Musabayane, professor of physiology at the University
of KwaZulu-Natal, and leader of a team of researchers who
discovered a new method of administering insulin into the
bloodstream via a skin patch. The discovery could eventually
pave the way for diabetic patients to control their insulin levels
in a pain-free manner with reduced negative side effects.
Musabayane was born and schooled in Zimbabwe, obtained
his BSc fromHertfordshire University in the UK, and then returned
to the University of Zimbabwe where he obtained his MSc and
In Memoriam: Cephas Musabayane, 1948–2015
PhD. He joined the University of KwaZulu-Natal as professor of
human physiology in 2003, and served as head of the School of
Medical Sciences for four years.
Musabayane was an academic who was passionate about
teaching and research. He inspired his students and motivated
them to achieve success. His areas of research included diabetes,
malaria and renal physiology, and he obtained national and
international recognition for his work. He was a life fellow of the
Physiology Society of Southern Africa and a member of the US
and UK physiological societies.